About this Series

Treatment advances are resulting in improved outcomes for patients with late-stage, non‒small cell lung cancer (NSCLC). Oncologists at UCLA Medical Center, Santa Monica, discuss benefits of immunotherapy used alone and in combination with chemotherapy in patients with advanced NSCLC, especially those who are treatment naive.

Disturbingly, many patients with late-stage NSCLC do not seek the care of cancer specialists, thinking they have no treatment options. But standard and emerging treatments for these patients have never been more effective. Early screening programs are also resulting in the diagnosis of NSCLC at earlier stages when the disease is potentially curable.

Show More

Who's Who
More on Lung Cancer